Go Pro
NASDAQ:QNTM

Quantum Biopharma Q4 2024 Earnings Report

Quantum Biopharma logo
$3.24 +0.29 (+9.83%)
As of 09/4/2026 04:00 PM Eastern

Quantum Biopharma EPS Results

Actual EPS
-$2.89
Consensus EPS
-$0.80
Beat/Miss
Missed by -$2.09
One Year Ago EPS
N/A

Quantum Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.92 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quantum Biopharma Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Quantum Biopharma's next earnings date is estimated for Friday, November 6, 2026, based on past reporting schedules.

Conference Call Resources

Quantum Biopharma Earnings Headlines

Rodman & Renshaw Initiates Coverage on Quantum Biopharma (NASDAQ:QNTM)
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Quantum Biopharma Provides Corporate Update
See More Quantum Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quantum Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quantum Biopharma and other key companies, straight to your email.

About Quantum Biopharma

Quantum Biopharma (NASDAQ:QNTM) is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

View Quantum Biopharma Profile